1. Home
  2. FGEN
  3. FGEN News

Latest FibroGen Inc (FGEN) News on November 18, 2025

FibroGen Inc (FGEN) Q3 2025 Earnings Call Highlights: Strategic Moves Bolster Financial ...
FGEN

GuruFocus.com

7 days ago

FibroGen Inc (FGEN) Q3 2025 Earnings Call Highlights: Strategic Moves Bolster Financial ...

FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
FGEN

Zacks

7 days ago

FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates

FGEN

Associated Press Finance

7 days ago

FibroGen: Q3 Earnings Snapshot

FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update
FGEN

GlobeNewswire

7 days ago

FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update

FibroGen to Report Third Quarter 2025 Financial Results
FGEN

GlobeNewswire

14 days ago

FibroGen to Report Third Quarter 2025 Financial Results

FGEN

MT Newswires

5 months ago

FibroGen to Implement 1-for-25 Reverse Stock Split

FibroGen Announces 1-for-25 Reverse Stock Split
FGEN

GlobeNewswire

5 months ago

FibroGen Announces 1-for-25 Reverse Stock Split

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
FGEN

GlobeNewswire

5 months ago

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

Top Asian Dividend Stocks To Consider In June 2025
FGEN

Simply Wall St.

5 months ago

Top Asian Dividend Stocks To Consider In June 2025

FGEN

Thomson Reuters StreetEvents

6 months ago

Q1 2025 FibroGen Inc Earnings Call

FibroGen Inc (FGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Cost Management Amid ...
FGEN

GuruFocus.com

6 months ago

FibroGen Inc (FGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Cost Management Amid ...

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
FGEN

Zacks

6 months ago

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

FGEN

Associated Press Finance

6 months ago

FibroGen: Q1 Earnings Snapshot

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
FGEN

GlobeNewswire

6 months ago

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

FibroGen to Report First Quarter 2025 Financial Results
FGEN

GlobeNewswire

6 months ago

FibroGen to Report First Quarter 2025 Financial Results

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
FGEN

GlobeNewswire

7 months ago

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
FGEN

GlobeNewswire

8 months ago

FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology

FibroGen Full Year 2024 Earnings: Beats Expectations
FGEN

Simply Wall St.

8 months ago

FibroGen Full Year 2024 Earnings: Beats Expectations

FGEN

Thomson Reuters StreetEvents

8 months ago

Q4 2024 FibroGen Inc Earnings Call

FibroGen Inc (FGEN) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines with ...
FGEN

GuruFocus.com

8 months ago

FibroGen Inc (FGEN) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines with ...

FGEN

Associated Press Finance

8 months ago

FibroGen: Q4 Earnings Snapshot

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
FGEN

GlobeNewswire

8 months ago

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
FGEN

GlobeNewswire

9 months ago

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

FibroGen sells China unit to AstraZeneca for $160m
FGEN

Pharmaceutical Technology

9 months ago

FibroGen sells China unit to AstraZeneca for $160m

FGEN

MT Newswires

9 months ago

FibroGen to Sell China Unit to AstraZeneca for $160 Million

AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal
FGEN

Reuters

9 months ago

AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million
FGEN

GlobeNewswire

9 months ago

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

AstraZeneca deepens China presence with FibroGen deal
FGEN

BioPharma Dive

9 months ago

AstraZeneca deepens China presence with FibroGen deal

Several Insiders Invested In FibroGen Flagging Positive News
FGEN

Simply Wall St.

9 months ago

Several Insiders Invested In FibroGen Flagging Positive News

FGEN

MT Newswires

a year ago

FibroGen Names David DeLucia CFO

FibroGen Appoints David DeLucia as Chief Financial Officer
FGEN

GlobeNewswire

a year ago

FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen Third Quarter 2024 Earnings: Beats Expectations
FGEN

Simply Wall St.

a year ago

FibroGen Third Quarter 2024 Earnings: Beats Expectations

FGEN

Thomson Reuters StreetEvents

a year ago

Q3 2024 FibroGen Inc Earnings Call

FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions
FGEN

GuruFocus.com

a year ago

FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions

FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates
FGEN

Zacks

a year ago

FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates

FGEN

Associated Press Finance

a year ago

FibroGen: Q3 Earnings Snapshot

FibroGen Reports Third Quarter 2024 Financial Results
FGEN

GlobeNewswire

a year ago

FibroGen Reports Third Quarter 2024 Financial Results

FibroGen to Report Third Quarter 2024 Financial Results
FGEN

GlobeNewswire

a year ago

FibroGen to Report Third Quarter 2024 Financial Results

FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts
FGEN

GuruFocus.com

a year ago

FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts

Duchenne muscular dystrophy: major trials and events to watch in 2023
FGEN

Clinical Trials Arena

a year ago

Duchenne muscular dystrophy: major trials and events to watch in 2023

FGEN

MT Newswires

a year ago

FibroGen Terminates CFO Juan Graham, Chief Medical Officer Deyaa Adib

FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FGEN

GlobeNewswire

a year ago

FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
FGEN

Simply Wall St.

a year ago

FibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
FGEN

Zacks

a year ago

FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates

FGEN

Associated Press Finance

a year ago

FibroGen: Q2 Earnings Snapshot

FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
FGEN

GlobeNewswire

a year ago

FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update

FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials
FGEN

Pharmaceutical Technology

a year ago

FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials

Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone
FGEN

BioPharma Dive

a year ago

Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone

FibroGen to Report Second Quarter 2024 Financial Results
FGEN

GlobeNewswire

a year ago

FibroGen to Report Second Quarter 2024 Financial Results

FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update
FGEN

GlobeNewswire

a year ago

FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update

FibroGen, Inc. (NASDAQ:FGEN) is a favorite amongst institutional investors who own 54%
FGEN

Simply Wall St.

a year ago

FibroGen, Inc. (NASDAQ:FGEN) is a favorite amongst institutional investors who own 54%

Favourable Signals For FibroGen: Numerous Insiders Acquired Stock
FGEN

Simply Wall St.

a year ago

Favourable Signals For FibroGen: Numerous Insiders Acquired Stock

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024
FGEN

GlobeNewswire

a year ago

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

FGEN

MT Newswires

a year ago

FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
FGEN

GlobeNewswire

a year ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FGEN

GlobeNewswire

a year ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
FGEN

GlobeNewswire

a year ago

FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN

GlobeNewswire

a year ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting

FibroGen First Quarter 2024 Earnings: Beats Expectations
FGEN

Simply Wall St.

2 years ago

FibroGen First Quarter 2024 Earnings: Beats Expectations

FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript
FGEN

Insider Monkey

2 years ago

FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript

FGEN

Thomson Reuters StreetEvents

2 years ago

Q1 2024 FibroGen Inc Earnings Call

FGEN

MT Newswires

2 years ago

Top Premarket Gainers

FibroGen to Participate in Upcoming Investor Conferences
FGEN

GlobeNewswire

2 years ago

FibroGen to Participate in Upcoming Investor Conferences

FGEN

GuruFocus.com

2 years ago

FibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...

FGEN

Associated Press Finance

2 years ago

FibroGen: Q1 Earnings Snapshot

FibroGen Reports First Quarter 2024 Financial Results
FGEN

GlobeNewswire

2 years ago

FibroGen Reports First Quarter 2024 Financial Results

FibroGen to Report First Quarter 2024 Financial Results
FGEN

GlobeNewswire

2 years ago

FibroGen to Report First Quarter 2024 Financial Results

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN

GlobeNewswire

2 years ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
FGEN

Zacks

2 years ago

Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies

Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
FGEN

Zacks

2 years ago

Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
FGEN

Zacks

2 years ago

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why

RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
FGEN

Zacks

2 years ago

RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
FGEN

Zacks

2 years ago

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
FGEN

Zacks

2 years ago

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study

Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
FGEN

Zacks

2 years ago

Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why

Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
FGEN

Zacks

2 years ago

Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
FGEN

GlobeNewswire

2 years ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
FGEN

Zacks

2 years ago

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
FGEN

Zacks

2 years ago

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
FGEN

GlobeNewswire

2 years ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
FGEN

Zacks

2 years ago

Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals

Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
FGEN

Zacks

2 years ago

Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data

Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
FGEN

Zacks

2 years ago

Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA

Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
FGEN

Zacks

2 years ago

Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag

Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
FGEN

Zacks

2 years ago

Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
FGEN

GlobeNewswire

2 years ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk
FGEN

Zacks

2 years ago

Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk

FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript
FGEN

Insider Monkey

2 years ago

FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript

US$1.25: That's What Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Is Worth After Its Latest Results
FGEN

Simply Wall St.

2 years ago

US$1.25: That's What Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Is Worth After Its Latest Results

FibroGen Full Year 2023 Earnings: Misses Expectations
FGEN

Simply Wall St.

2 years ago

FibroGen Full Year 2023 Earnings: Misses Expectations

FGEN

Thomson Reuters StreetEvents

2 years ago

Q4 2023 FibroGen Inc Earnings Call

FGEN

Associated Press Finance

2 years ago

FibroGen: Q4 Earnings Snapshot

FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023
FGEN

GuruFocus.com

2 years ago

FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023

FGEN

Reuters

2 years ago

UPDATE 1-FibroGen regains rights to anemia drug from AstraZeneca

FGEN

Reuters

2 years ago

FibroGen regains rights to anemia drug from AstraZeneca

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
FGEN

GlobeNewswire

2 years ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
FGEN

GlobeNewswire

2 years ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
FGEN

GlobeNewswire

2 years ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
FGEN

GlobeNewswire

2 years ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

/C O R R E C T I O N -- Nutex Health, Inc./
FGEN

PR Newswire

2 years ago

/C O R R E C T I O N -- Nutex Health, Inc./

Share on Social Networks: